Perspectives on cancer therapy with radiolabeled monoclonal antibodies

Journal of Nuclear Medicine

Volumn 46, Issue 1 SUPPL., 2005, Pages

  Sharkey, Robert M ^a   Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

Antibodies; Colorectal cancer; Non Hodgkin's lymphoma; Pretargeting; Radioimmunotherapy

Indexed keywords

CD20 ANTIBODY; EPRATUZUMAB; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; ONCOLYM; RADIOPHARMACEUTICAL AGENT; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; RADIOISOTOPE;

ARTICLE; CANCER THERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; HYPOTHYROIDISM; ISOTOPE LABELING; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOACTIVITY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; ANIMAL; DRUG DELIVERY SYSTEM; METHODOLOGY; NEOPLASM; RADIOIMMUNOTHERAPY; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG DELIVERY SYSTEMS; HUMANS; LYMPHOMA, NON-HODGKIN; NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 14844343723     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (202)

1. Pressman D, Korngold L. The in vivo localization of anti-wagner osteogenic-sarcoma antibodies. Cancer. 1953;6:619-623.
2. Goldenberg DM, DeLand F, Kim E, et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med. 1978;298:1384-1386.
3. Goldenberg DM, Juweid M, Dunn RM, Sharkey RM. Cancer imaging with radiolabeled antibodies: new advances with technetium-99m-labeled monoclonal antibody Fab′ fragments, especially CEA-scan and prospects for therapy. J Nucl Med Technol. 1997;25:18-23.
4. Goldenberg DM. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol. 2001;39:195-201.
5. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;43:693-713.
6. Dean NM, Bennett CF. Antisense oligonucleotide-based therapeutics for cancer. Oncogene. 2003;22:9087-9096.
7. Britz-Cunningham SH, Adelstein SJ. Molecular targeting with radionuclides: state of the science. J Nucl Med. 2003;44:1945-1961.
8. Chanan-Khan A, Czuczman MS. Radioimmunotherapy in non-Hodgkin lymphoma. Curr Opin Oncol. 2002;14:484-489.
9. Press OW. Radioimmunotherapy for non-Hodgkin's lymphomas: a historical perspective. Semin Oncol. 2003;30:10-21.
10. Silverman DH, Delpassand ES, Torabi F, Goy A, McLaughlin P, Murray JL. Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues. Cancer Treat Rev. 2004;30:165-172.
11. Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood. 2003;101:391-398.
12. Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother. 2003;52:281-296.
13. Russeva MG, Adams GP. Radioimmunotherapy with engineered antibodies. Expert Opin Biol Ther. 2004;4:217-231.
14. Bethge WA, Sandmaier BM. Targeted cancer therapy and immunosuppression using radiolabeled monoclonal antibodies. Semin Oncol. 2004;31:68-82.
15. Zevalin (ibritumomab tiuxetan) [package insert]. San Diego, CA: IDEC Pharmaceuticals Corporation; 2002.
16. 131I-tositumomab) [package insert]. Seattle, WA: Corixa Corporation and Philadelphia, PA: GlaxoSmithKline; 2003.
17. Press OW, Shan D, Howell-Clark J, et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 1996;56:2123-2129.
18. Sharkey RM, Behr TM, Mattes MJ, et al. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother. 1997;44:179-188.
19. 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin Cancer Res. 1999;5:3292S-3303S.
20. DeNardo GL, DeNardo SJ, O'Donnell RT, et al. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma. Clin Lymphoma. 2000;1:118-126.
21. 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med. 2002;43:267-272.
22. 131I- tositumomab therapy. J Nucl Med. 2002;43:354-363.
23. Leonard JP, Siegel JA, Goldsmith SJ. Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma. Cancer Invest. 2003;21:241-252.
24. 90Y-Ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. J Nucl Med Technol. 2003;31:61-68.
25. 90Y-ibritumomab tiuxetan. J Nucl Med. 2004;45:450-454.
26. Vose JM. Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma. Oncologist. 2004;9:160-172.
27. Koral KF, Dewaraja Y, Clarke LA, et al. Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: preliminary report. Cancer Biother Radiopharm. 2000;15:347-355.
28. Koral KF, Kaminski MS, Wahl RL. Correlation of tumor radiation-absorbed dose with response is easier to find in previously untreated patients. J Nucl Med. 2003;44:1541-1543.
29. 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med. 2003;44:260-268.
30. 90Y-epratuzumab): Do tumor targeting and dosimetry predict therapeutic response? J Nucl Med. 2003;44:2000-2018.
31. Rastetter W, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med. 2004;55:477-503.
32. Coleman M, Goldenberg DM, Siegel AB, et al. Epratuzumab: targeting B-cell malignancies through CD22. Clin Cancer Res. 2003;9:3991S-3994S.
33. 90Y ibritumomab tiuxetan (zevalin). Semin Oncol. 2003;30(suppl):6-10.
34. Du Y, Honeychurch J, Cragg MS, et al. Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood. 2004;103:1485-1494.
35. 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259-1266.
36. + B-cell lymphoma: long term follow-up of a phase I/II study. Blood. 2004;103:4429-4431.
37. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 2004;103:2738-2743.
38. Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol. 2003;30(suppl):3-8.
39. 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res. 1992;52:6476-6481.
40. 131I]anti-B1 (anti-CD20) antibody. N Engl J Med. 1993;329:459-465.
41. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001;19:3918-3928.
42. Leonard JP, Coleman M, Ketas JC, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol. 2003;21:3051-3059.
43. Dechant M, Bruenke J, Valerius T. HLA class II antibodies in the treatment of hematologic malignancies. Semin Oncol. 2003;30:465-475.
44. Kaminski M, Estes J, Tuck M, et al. Iodine I 131 tositumomab therapy for previously untreated follicular lymphoma [abstract]. Proc ASCO. 2000;19:5a.
45. Press OW, Unger JM, Braziel RM, et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood. 2003;102:1606-1612.
46. Rana TM. Post Bexxar relapse in NHL responds to Zevalin and can be safely accomplished [abstract]. Proc Am Soc Clin Oncol. 2003;22:613.
47. Tsai DE, Maillard I, Schuster SJ, et al. Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody. Clin Lymphoma. 2003;4:56-59.
48. Ansell SM, Ristow KM, Habermann TM, Wiseman GA, Witzig TE. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:3885-3890.
49. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med. 2003;44:465-474.
50. Siegel JA, Yeldell D, Goldenberg DM, et al. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. J Nucl Med. 2003;44:67-76.
51. Pagel JM, Matthews DC, Appelbaum FR, Bernstein ID, Press OW. The use of radioimmunoconjugates in stem cell transplantation. Bone Marrow Transplant. 2002;29:807-816.
52. Gopal AK, Rajendran JG, Petersdorf SH, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood. 2002;99:3158-3162.
53. 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood. 1999;94:1237-1247.
54. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96:2934-2942.
55. Burke JM, Caron PC, Papadopoulos EB, et al. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant. 2003;32:549-556.
56. Buchmann I, Bunjes D, Kotzerke J, et al. Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities. Cancer Biother Radiopharm. 2002;17:151-163.
57. 131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer Biother Radiopharm. 2003;18:513-524.
58. Lindén O, Tennvall J, Cavallin-Ståhl, et al. A phase I/II trial with Y-90 hLL2 in recurrent B-cell lymphomas. Preliminary results [abstract]. Cancer Biother Radiopharm. 2000;15:413.
59. 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. Anticancer Res. 2000;20:3647-3655.
60. Gopal AK, Gooley TA, Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood. 2003;102:2351-2357.
61. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood. 2002;100:1233-1239.
62. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science. 2001;294:1537-1540.
63. 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med. 1999;40:1935-1946.
64. 90yttrium. Clin Cancer Res. 2001;7:1505-1510.
65. Hansen HJ, Ong GL, Diril H, et al. Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas. Biochem J. 1996;320:293-300.
66. Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol. 2001;39:181-194.
67. Tempero M, Leichner P, Dalrymple G, et al. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. J Clin Oncol. 1997;15:1518-1528.
68. Tempero M, Leichner P, Baranowska-Kortylewicz J, et al. High-dose therapy with 90yttrium-labeled monoclonal antibody CC49: a phase I trial. Clin Cancer Res. 2000;6:3095-3102.
69. 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clin Cancer Res. 1996;2:1811-1818.
70. Meredith R, Shen S, Macey D, et al. Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy. Cancer Biother Radiopharm. 2003;18:393-404.
71. 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin Cancer Res. 1999;5:3254S-3258S.
72. Mulligan T, Carrasquillo JA, Chung Y, et al. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin Cancer Res. 1995;1:1447-1454.
73. 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin Cancer Res. 2000;6:3855-3863.
74. 131I-labeled murine monoclonal antibody to carcinoembryonic antigen. Cancer Res. 1987;47:5672-5677.
75. Sharkey RM, Weadock KS, Natale A, et al. Successful radioimmunotherapy for lung metastasis of human colonic cancer in nude mice. J Natl Cancer Inst. 1991;83:627-632.
76. Boerman OC, Sharkey RM, Blumenthal RD, Aninipot RL, Goldenberg DM. The presence of a concomitant bulky tumor can decrease the uptake and therapeutic efficacy of radiolabeled antibodies in small tumors. Int J Cancer. 1992;51:470-475.
77. Moshakis V, McIlhinney RA, Raghavan D, Neville AM. Localization of human tumour xenografts after i.v. administration of radiolabeled monoclonal antibodies. Br J Cancer. 1981;44:91-99.
78. Mayer A, Tsiompanou E, Flynn AA, et al. Higher dose and dose-rate in smaller tumors result in improved tumor control. Cancer Invest. 2003;21:382-388.
79. 131I-labeled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res. 1990;50:1039S-1042S.
80. 131I-CC49 in colorectal cancer. Cancer. 1994;73(suppl):1057-1066.
81. Behr TM, Liersch T, Greiner-Bechert L, et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer. 2002;94(suppl):1373-1381.
82. Liersch T, Behr TM, Becker W, et al. Effect of CEA radioimmunotherapy post salvage resection of colorectal cancer liver metastases: phase II safety and outcome results [abstract]. Proc GI Cancer Symp. 2003;160.
83. Fong Y. Surgical therapy of hepatic colorectal cancer metastasis. CA Cancer J Clin. 1999;49:231-255.
84. Williams LE, Wu AM, Yazaki PJ, et al. Numerical selection of optimal tumor imaging agents with application to engineered antibodies. Cancer Biother Radiopharm. 2001;16:25-35.
85. Casey JL, Pedley RB, King DJ, Green AJ, Yarranton GT, Begent RH. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab′ fragments. Br J Cancer. 1999;81:972-980.
86. Behr TM, Memtsoudis S, Sharkey RM, et al. Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: influence of radiation dose and dose rate on toxicity and anti-tumor efficacy. Int J Cancer. 1998;77:787-795.
87. Behr TM, Blumenthal RD, Memtsoudis S, et al. Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments. Clin Cancer Res. 2000;6:4900-4907.
88. 131I-labelled antibodies and their fragments in the GW-39 colonic cancer xenograft model. Int J Cancer. 1989;44:292-300.
89. 2 fragment in nude mice bearing different human colon cancer xenografts. Br J Cancer. 1993;68:684-690.
90. 131I-labeled multivalent CC49 single-chain Fvs. Clin Cancer Res. 2001;7:175-184.
91. Wu AM. Engineering multivalent antibody fragments for in vivo targeting. Methods Mol Biol. 2004;248:209-225.
92. Slavin-Chiorini DC, Kashmiri SV, Lee HS, et al. A CDR-grafted (humanized) domain-deleted antitumor antibody. Cancer Biother Radiopharm. 1997;12:305-316.
93. Goel A, Colcher D, Baranowska-Kortylewicz J, et al. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application. Cancer Res. 2000;60:6964-6971.
94. Yazaki PJ, Wu AM, Tsai SW, et al. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments. Bioconjug Chem. 2001;12:220-228.
95. Behr TM, Sharkey RM, Juweid ME, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res. 1995;55:3825-3834.
96. Behr TM, Sharkey RM, Sgouros G, et al. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer. 1997;80(suppl):2591-2610.
97. 86Y-DOTA0-D-Phe1-Tyr3- octreotide (SMT487) - a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging. 2003;30:510-518.
98. 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging. 2003;30:207-216.
99. Moll S, Nickeleit V, Mueller-Brand J, Brunner FP, Maecke HR, Mihatsch MJ. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis. 2001;37:847-851.
100. 90Y-DOTATOC. Eur J Nucl Med. 2001;28:1552-1554.
101. Forero A, Meredith RF, Khazaeli MB, et al. A novel monoclonal antibody design for radioimmunotherapy. Cancer Biother Radiopharm. 2003;18:751-759.
102. Rowlinson G, Snook D, Busza A, Epenetos AA. Antibody-guided localization of intraperitoneal tumors following intraperitoneal or intravenous antibody administration. Cancer Res. 1987;47:6528-6531.
103. Ward BG, Wallace K. Localization of the monoclonal antibody HMFG2 after intravenous and intraperitoneal injection into nude mice bearing subcutaneous and intraperitoneal human ovarian cancer xenografts. Cancer Res. 1987;47:4714-4718.
104. Wahl RL, Barrett J, Geatti O, et al. The intraperitoneal delivery of radiolabeled monoclonal antibodies: studies on the regional delivery advantage. Cancer Immunol Immunother. 1988;26:187-201.
105. Griffin TW, Collins J, Bokhari F, et al. Intraperitoneal immunoconjugates. Cancer Res. 1990;50:1031S-1038S.
106. Kinuya S, Li XF, Yokoyama K, et al. Intraperitoneal radioimmunotherapy in treating peritoneal carcinomatosis of colon cancer in mice compared with systemic radioimmunotherapy. Cancer Sci. 2003;94:650-654.
107. Colcher D, Esteban J, Carrasquillo JA, et al. Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res. 1987;47:4218-4224.
108. Juweid M, Sharkey RM, Alavi A, et al. Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibody. J Nucl Med. 1997;38:257-260.
109. Juweid M, Swayne LC, Sharkey RM, et al. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies. Gynecol Oncol. 1997;67:259-271.
110. Epenetos AA, Hird V, Lambert H, Mason P, Coulter C. Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int J Gynecol Cancer. 2000;10:44-46.
111. 177Lu-CC49: a phase I/II study. Gynecol Oncol. 1997;65:94-101.
112. Bigner DD, Brown MT, Friedman AH, et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol. 1998;16:2202-2212.
113. 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2002;20:1389-1397.
114. Akabani G, Cokgor I, Coleman RE, et al. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int J Radiat Oncol Biol Phys. 2000;46:947-958.
115. Grossi PM, Ochiai H, Archer GE, et al. Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res. 2003;9:5514-5520.
116. 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys. 2004;58:972-975.
117. Greiner JW, Guadagni F, Noguchi P, et al. Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. Science. 1987;235:895-898.
118. Stickney DR, Gridley DS, Kirk GA, Slater JM. Enhancement of monoclonal antibody binding to melanoma with single dose radiation or hyperthermia. Nat Cancer Inst Monogr. 1987;3:47-52.
119. Hauck ML, Dewhirst MW, Bigner DD, Zalutsky MR. Local hyperthermia improves uptake of a chimeric monoclonal antibody in a subcutaneous xenograft model. Clin Cancer Res. 1997;3:63-70.
120. Vogel CA, Galmiche MC, Buchegger F. Radioimmunotherapy and fractionated radiotherapy of human colon cancer liver metastases in nude mice. Cancer Res. 1997;57:447-453.
121. Kinuya S, Yokoyama K, Hiramatsu T, et al. Optimal timing of administration of hyperthermia in combined radioimmunotherapy. Cancer Biother Radiopharm. 2000;15:373-379.
122. Ruan S, O'Donoghue JA, Larson SM, et al. Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam. J Nucl Med. 2000;41:1905-1912.
123. Saga T, Sakahara H, Nakamoto Y, et al. Enhancement of the therapeutic outcome of radio-immunotherapy by combination with whole-body mild hyperthermia. Eur J Cancer. 2001;37:1429-1434.
124. Pedley RB, Boden JA, Boden R, et al. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res. 1996;56:3293-3300.
125. Pedley RB, Hill SA, Boxer GM, et al. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res. 2001;61:4716-4722.
126. Pedley RB, El-Emir E, Flynn AA, et al. Synergy between vascular targeting agents and antibody-directed therapy. Int J Radiat Oncol Biol Phys. 2002;54:1524-1531.
127. Kurizaki T, Okazaki S, Sanderson SD, et al. Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a. J Nucl Med. 2002;43:957-967.
128. Li XF, Kinuya S, Yokoyama K, et al. Benefits of combined radioimmunotherapy and anti-angiogenic therapy in a liver metastasis model of human colon cancer cells. Eur J Nucl Med Mol Imaging. 2002;29:1669-1674.
129. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res. 2002;62:4263-4272.
130. Kinuya S, Kawashima A, Yokoyama K, et al. Anti-angiogenic therapy and radioimmunotherapy in colon cancer xenografts. Eur J Nucl Med. 2001;28:1306-1312.
131. Buchsbaum DJ. Imaging and therapy of tumors induced to express somatostatin receptor by gene transfer using radiolabeled peptides and single chain antibody constructs. Semin Nucl Med. 2004;34:32-46.
132. DeNardo SJ, Kukis DL, Kroger LA, et al. Synergy of taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci USA. 1997;94:4000-4004.
133. DeNardo SJ, Kroger LA, Lamborn KR, et al. Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma. Cancer. 1997;80(suppl):2583-2590.
134. Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy. Clin Cancer Res. 2000;6:3621-3628.
135. 90yttrium-DOTA-peptide-ChL6. Prostate. 2002;50:27-37.
136. Ng B, Kramer E, Liebes L, et al. Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts. Cancer Res. 2001;61:2996-3001.
137. 90yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft. Int J Cancer. 2004;109:618-626.
138. Burke PA, DeNardo SJ, Miers LA, Kukis DL, DeNardo GL. Combined modality radioimmunotherapy: promise and peril. Cancer. 2002;94(suppl):1320-1331.
139. Blumenthal RD, Leone E, Goldenberg DM. Tumor-specific dose scheduling of bimodal radioimmunotherapy and chemotherapy. Anticancer Res. 2003;23:4613-4619.
140. Blumenthal RD, Leone E, Goldenberg DM, Rodriguez M, Modrak D. An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expression. Int J Cancer. 2004;108:293-300.
141. Chalandon Y, Mach JP, Pelegrin A, Folli S, Buchegger F. Combined radioimmunotherapy and chemotherapy of human colon carcinoma grafted in nude mice, advantages and limitations. Anticancer Res. 1992;12:1131-1139.
142. 131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil). Cancer Res. 1997;57:2181-2186.
143. Cardillo TM, Blumenthal R, Ying Z, Gold DV. Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer. Int J Cancer. 2002;97:386-392.
144. 90Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer. Clin Cancer Res. 2003;9:3929s-3937s.
145. Behr TM, Wulst E, Radetzky S, et al. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res. 1997;57:5309-5319.
146. Stein R, Chen S, Reed L, Richel H, Goldenberg DM. Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazine. Cancer. 2002;94:51-61.
147. Meredith RF, Alvarez RD, Partridge EE, et al. Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study. Cancer Biother Radiopharm. 2001;16:305-315.
148. 90yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res. 2002;8:2806-2811.
149. 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res. 2003;9:5842-5852.
150. Paganelli G, Magnani P, Fazio F. Pretargeting of carcinomas with the avidin-biotin system. Int J Biol Markers. 1993;8:155-159.
151. Barbet J, Kraeber-Bodere F, Vuillez JP, Gautherot E, Rouvier E, Chatal JF. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm. 1999;14:153-166.
152. Goodwin DA, Meares CF. Advances in pretargeting biotechnology. Biotechnol Adv. 2001;19:435-450.
153. Gruaz-Guyon A, Janevik-Ivanovska E, Raguin O, De Labriolle-Vaylet C, Barbet J. Radiolabeled bivalent haptens for tumor immunodetection and radioimmunotherapy. Q J Nucl Med. 2001;45:201-206.
154. McQuarrie SA, Xiao Z, Miller GG, Mercer JR, Suresh MR. Modern trends in radioimmunotherapy of cancer: pretargeting strategies for the treatment of ovarian cancer. Q J Nucl Med. 2001;45:160-166.
155. Chang CH, Sharkey RM, Rossi EA, et al. Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol Cancer Ther. 2002;1:553-563.
156. Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH. Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med. 2003;44:400-411.
157. Reardan DT, Meares CF, Goodwin DA, et al. Antibodies against metal chelates. Nature. 1985;316:265-268.
158. Stickney DR, Anderson LD, Slater JB, et al. Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma. Cancer Res. 1991;51:6650-6655.
159. Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med. 1989;30:1358-1366.
160. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med. 1987;28:1294-1302.
161. Paganelli G, Pervez S, Siccardi AG, et al. Intraperitoneal radio-localization of tumors pre-targeted by biotinylated monoclonal antibodies. Int J Cancer. 1990;45:1184-1189.
162. Paganelli G, Magnani P, Zito F, et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res. 1991;51:5960-5906.
163. Paganelli G, Chinol M. Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur J Nucl Med Mol Imaging. 2003;30:773-776.
164. Goldenberg DM, Chang CH, Sharkey RM, et al. Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur J Nucl Med Mol Imaging. 2003;30:777-780.
165. Rossi EA, Sharkey RM, McBride W, et al. Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. Clin Cancer Res. 2003;9:3886S-3896S.
166. 99mTc morpholino pretargeting in mice. Nucl Med Commun. 2003;24:697-705.
167. 99mTc. Nucl Med Biol. 2003;30:207-214.
168. Liu G, He J, Dou S, et al. Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake. Eur J Nucl Med Mol Imaging. 2004;31:417-424.
169. Kalofonos HP, Rusckowski M, Siebecker DA, et al. Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication. J Nucl Med. 1990;31:1791-1796.
170. Peltier P, Curtet C, Chatal JF, et al. Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J Nucl Med. 1993;34:1267-1773.
171. Le Doussal JM, Chetanneau A, Gruaz-Guyon A, et al. Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. J Nucl Med. 1993;34:1662-1671.
172. Dosio F, Magnani P, Paganelli G, Samuel A, Chiesa G, Fazio F. Three-step tumor pre-targeting in lung cancer immunoscintigraphy. J Nucl Biol Med. 1993;37:228-232.
173. Modorati G, Brancato R, Paganelli G, Magnani P, Pavoni R, Fazio F. Immunoscintigraphy with three-step monoclonal pretargeting technique in diagnosis of uveal melanoma: preliminary results. Br J Ophthalmol. 1994;78:19-23.
174. 90Y radioimmunotherapy in a mouse xenograft model [abstract]. J Immunother. 1994;16:158.
175. Gautherot E, Bouhou J, Le Doussal JM, et al. Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten. Cancer. 1997;80(suppl):2618-2623.
176. Gautherot E, Le Doussal JM, Bouhou J, et al. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens. J Nucl Med. 1998;39:1937-1943.
177. Kraeber-Bodere F, Faivre-Chauvet A, Sai-Maurel C, et al. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab′)2 and pretargeted bivalent hapten and evaluation of repeated injections. Clin Cancer Res. 1999;5(suppl):3183S-3189S.
178. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA. 2000;97:1802-1807.
179. 131I- labeled bivalent hapten. J Nucl Med. 2000;41:480-487.
180. Press OW, Corcoran M, Subbiah K, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood. 2001;98:2535-2543.
181. 90Y-labeled 1,4,7,10-tetraazacyclododecane-N,N′,N″, N‴-tetraacetic acid (DOTA)-biotin. Cancer Res. 2002;62:5755-5760.
182. Zhang M, Yao Z, Garmestani K, et al. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. Blood. 2002;100:208-216.
183. Subbiah K, Hamlin DK, Pagel JM, et al. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. J Nucl Med. 2003;44:437-445.
184. Zhang M, Zhang Z, Garmestani K, et al. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci USA. 2003;100:1891-1895.
185. 64Cu for tumor imaging and therapy. J Nucl Med. 2003;44:1284-1292.
186. Sharkey RM, Karacay H, Richel H, et al. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. Clin Cancer Res. 2003;9:3897S-3913S.
187. Cremonesi M, Ferrari M, Chinol M, et al. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients. Eur J Nucl Med. 1999;26:110-120.
188. Kraeber-Bodere F, Bardet S, Hoefnagel CA, et al. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial. Clin Cancer Res. 1999;5:3190S-3198S.
189. Vuillez JP, Kraeber-Bodere F, Moro D, et al. Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 di-DTPA hapten: results of a phase I/II trial. Clin Cancer Res. 1999;5:3259S-3267S.
190. Weiden PL, Breitz HB, Press O, et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm. 2000;15:15-29.
191. Kraeber-Bodere F, Faivre-Chauvet A, Ferrer L, et al. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clin Cancer Res. 2003;9:3973S-3981S.
192. Knox SJ, Goris ML, Tempero M, et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res. 2000;6:406-414.
193. 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin. Cancer Biother Radiopharm. 1999;14:381-395.
194. 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. Cancer Biother Radiopharm. 2001;16:227-235.
195. Grana C, Chinol M, Robertson C, et al. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br J Cancer. 2002;86:207-212.
196. Weiden PL, Breitz HB. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL). Crit Rev Oncol Hematol. 2001;40:37-51.
197. Forero A, Weiden PL, Vose JM, et al. Phase I trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin's lymphoma. Blood. 2004;104:227-236.
198. Paganelli G, Orecchia R, Jereczek-Fossa B, et al. Combined treatment of advanced oropharyngeal cancer with external radiotherapy and three-step radioimmunotherapy. Eur J Nucl Med. 1998;25:1336-1339.
199. Kraeber-Bodere F, Sai-Maurel C, Campion L, et al. Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. Mol Cancer Ther. 2002;1:267-274.
200. Graves SS, Dearstyne E, Lin Y, et al. Combination therapy with pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. Clin Cancer Res. 2003;9:3712-3721.
201. Meares CF, Chmura AJ, Orton MS, Corneillie TM, Whetstone PA. Molecular tools for targeted imaging and therapy of cancer. J Mol Recognit. 2003;16:255-259.
202. Blumenthal RD, Sharkey RM, Natale AM, Kashi R, Wong G, Goldenberg DM. Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts. Cancer Res. 1994;54:142-151.